Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Merck & Co has joined the bid to grab a slice of the market for Sanofi's big-selling diabetes drug Lantus by licensing a biosimilar candidate originally developed by Korea's Samsung Bioepis.
Merck first announced its collaboration with Samsung a year ago, revealing that the two companies would be working on a number of biosimilar candidates but declining to reveal their identity.
Now, the two firms have confirmed that the lead project will be MK-1293, a biosimilar of Sanofi's basal insulin Lantus (insulin glargine), which is the French company's top-selling drug with turnover rising nearly 19 per cent to ?5.72bn ($7.8bn) last year.
http://www.pmlive.com/pharma_news/merck_joins_biosimilar_lantus_race_542704
Merck first announced its collaboration with Samsung a year ago, revealing that the two companies would be working on a number of biosimilar candidates but declining to reveal their identity.
Now, the two firms have confirmed that the lead project will be MK-1293, a biosimilar of Sanofi's basal insulin Lantus (insulin glargine), which is the French company's top-selling drug with turnover rising nearly 19 per cent to ?5.72bn ($7.8bn) last year.
http://www.pmlive.com/pharma_news/merck_joins_biosimilar_lantus_race_542704